PUBLISHER: The Business Research Company | PRODUCT CODE: 1957674
PUBLISHER: The Business Research Company | PRODUCT CODE: 1957674
Porcine epidemic diarrhea vaccines are biological preparations designed to induce immunity against the porcine epidemic diarrhea virus, which leads to severe gastrointestinal illness in pigs. These vaccines play a crucial role in preventing and managing porcine epidemic diarrhea, supporting the health and productivity of pig herds and the economic stability of the swine industry.
The primary products of porcine epidemic diarrhea vaccines include live vaccines and inactivated vaccines. Live vaccines are biological formulations that contain attenuated or weakened versions of the porcine epidemic diarrhea virus (PEDV). Their applications encompass piglets and adult pigs and are utilized by various end-users, including veterinary clinics and hog production farms.
Tariffs have impacted the porcine epidemic diarrhea vaccines market by increasing the cost of imported vaccine raw materials, biological components, and cold-chain logistics equipment. These effects are most visible in live and inactivated vaccines supplied across major swine-producing regions such as Asia-Pacific and North America. Higher input costs have influenced vaccine pricing for hog production farms and veterinary hospitals. However, tariffs have also encouraged local vaccine manufacturing and strengthened regional self-sufficiency in animal health solutions.
The porcine epidemic diarrhea vaccines market research report is one of a series of new reports from The Business Research Company that provides porcine epidemic diarrhea vaccines market statistics, including porcine epidemic diarrhea vaccines industry global market size, regional shares, competitors with a porcine epidemic diarrhea vaccines market share, detailed porcine epidemic diarrhea vaccines market segments, market trends and opportunities, and any further data you may need to thrive in the porcine epidemic diarrhea vaccines industry. This porcine epidemic diarrhea vaccines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The porcine epidemic diarrhea vaccines market size has grown strongly in recent years. It will grow from $1.8 billion in 2025 to $1.94 billion in 2026 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to recurring outbreaks of porcine epidemic diarrhea, high mortality rates in neonatal piglets, economic losses in the swine industry, limited effectiveness of non-vaccine disease control measures, increased reliance on veterinary-led disease prevention.
The porcine epidemic diarrhea vaccines market size is expected to see strong growth in the next few years. It will grow to $2.5 billion in 2030 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to growth of intensive pig farming practices, rising global demand for pork products, increasing awareness of herd immunity benefits, expansion of organized hog production farms, supportive government animal health initiatives. Major trends in the forecast period include increasing adoption of preventive vaccination in swine health management, growing preference for live vaccines in endemic regions, rising focus on early immunization of piglets, expansion of vaccination programs in commercial hog farms, greater emphasis on biosecurity and disease control protocols.
The growth of pig farming is expected to drive the expansion of the porcine epidemic diarrhea vaccine market in the coming years. Pig farming entails raising domestic pigs for meat production, breeding, rearing, managing animals from birth to market weight, and producing and marketing pork products. The increase in pig farming is fueled by rising global demand for pork, improvements in breeding and herd management practices, technological advancements in swine production systems, and the growth of commercial pork markets. Porcine epidemic diarrhea (PED) vaccines are essential in pig farming, helping prevent and control disease outbreaks, with administration typically occurring during the sow's gestation period to provide passive immunity to newborn piglets. For example, in April 2024, the U.S. Department of Agriculture, a US-based government agency, projected U.S. pork production to reach 12.7 million metric tons, indicating increased swine output and supporting the ongoing growth of the pig farming industry. Consequently, the rise in pig farming is contributing to the expansion of the porcine epidemic diarrhea vaccine market.
Major companies operating in the Porcine Epidemic Diarrhea (PED) vaccines market are concentrating on creating innovative solutions such as next-generation inactivated and recombinant vaccines to boost immunity and offer broader protection against emerging PEDV strains. Next-generation inactivated and recombinant vaccines are advanced vaccines that utilize either killed viruses or engineered viral proteins to elicit strong, targeted immunity while enhancing safety and defense against evolving disease strains. For example, in August 2024, Zoetis Inc., a US-based animal health company, received a grant for Porcine Epidemic Diarrhea Virus (PEDV) vaccine research and was also granted a conditional license by the U.S. Department of Agriculture (USDA) for a vaccine to combat PEDV in pigs. These initiatives reinforce Zoetis's position in developing advanced swine health solutions by supporting continued research, improving vaccine efficacy, and expanding protection against emerging PEDV strains.
In November 2024, Phibro Animal Health Corporation, a US-based health company, completed the acquisition of Zoetis Inc. for an undisclosed sum. The acquisition is intended to expand Phibro's product range in medicated feed additives and water-soluble products for cattle, swine, and poultry, enhancing its capacity to support animal health and nutrition globally. It also aims to boost Phibro's profitability, grow its revenue base, and provide capital for future investments in the animal health sector. Zoetis Inc. is a pharmaceutical manufacturing company that focuses on producing porcine epidemic diarrhea vaccines.
Major companies operating in the porcine epidemic diarrhea vaccines market are Zoetis Inc., Merck Animal Health, MSD Animal Health, Elanco Animal Health, Boehringer Ingelheim Animal Health, Ceva Sante Animale, Phibro Animal Health Corporation, IDT Biologika GmbH, Vaxxinova, Qilu Animal Health Products Factory Co. Ltd., Green Cross Veterinary Products Co. Ltd., Nisseiken Co. Ltd., Ourofino Saude Animal, Medgene Labs, Harrisvaccines Inc., Tecnovax, Komipharm International Co. Ltd., Bioveta a.s., HIPRA, CZ Vaccines
Asia-Pacific was the largest region in the porcine epidemic diarrhea vaccines market in 2025. The regions covered in the porcine epidemic diarrhea vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the porcine epidemic diarrhea vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The porcine epidemic diarrhea vaccines market consists of sales of ingelvac PEDV, barricade, PED vax, PEDV shield, and enterisol ileitis. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Porcine Epidemic Diarrhea Vaccines Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses porcine epidemic diarrhea vaccines market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for porcine epidemic diarrhea vaccines ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The porcine epidemic diarrhea vaccines market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.